BenevolentAI, in partnership with the Association of Medical Research Charities (“AMRC”) announced today it is running the ‘BenevolentAI Award’ for a second year following the success of its work with previous winners, Parkinson’s UK and Cure Parkinson’s Trust.

Every year, the World Economic Forum welcomes leading early-stage technology companies from around the world into its Technology Pioneer’s community. In its own words, these companies are “poised to have a significant impact on business and society”. Today we are delighted and humbled to be named as one such Technology Pioneer.

Digital entrepreneur Joanna Shields joins BenevolentAI as Group CEO. Experienced executive, and prominent leader in the global technology industry with a track record of growing some of the world’s best-known transformational technology companies.

BenevolentAI will use its technology platform to comprehensively review and understand the millions of data sets, pin-point important research areas and ways of preventing age-related macular degeneration and potential treatments (AMD)

BenevolentAI acquires clinical development research facility in Cambridge to drive AI drug discovery. Acquisition creates first AI company capable of covering entire drug development process from drug discovery to clinical development.

BenevolentAI and Association of Medical Research Charities (AMRC) create ‘BenevolentAI Award’ to help charities accelerate medical research and potentially develop new treatments and therapies using artificial intelligence.

Ian Churcher joins BenevolentAI as its new VP of Drug Discovery & Preclinical Development He joins BenevolentAI from GSK where he headed a Discovery Performance Unit focussed on progressing new approaches to drug discovery including pioneering development of Protein Degradation technology.

Dr Nathan Brown joins BenevolentAI as new Head of Cheminformatics. He has extensive experience as a software designer and has developed many novel algorithms to maximise the impact of the experimental data generated in medicinal chemistry and cancer biology.

BenevolentAI has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by the Johnson & Johnson Innovation Centre in London.

Jackie Hunter PhD CBE FBPharmacolS FMedSci, currently the Chief Executive of the Biotechnology and Biological Sciences Research Council (BBSRC), announced today that she will leave the BBSRC to become CEO of BenevolentBio, a business unit of BenevolentAI, a pioneering London-based technology company that applies artificial intelligence to transform the process of drug discovery in the pharmaceutical industry.